Author

Paul Sevelda

Observed names: P Sevelda, P. Sevelda, PAUL SEVELDA, Sevelda P, Sevelda, Paul

Observed institutions: Goethe University Frankfurt, Novartis (Switzerland), University of Vienna, Amgen (United States), Siemens (Germany), Innsbruck Medical University, Tel Aviv University, Universität Innsbruck, Hebrew University of Jerusalem, Johannes Gutenberg University Mainz, Medical University of Graz, Cornell University, Paracelsus Medical University, Wolfson Medical Center, Vienna General Hospital, Karolinska Institutet, Donauspital, Klinik Hietzing, Comprehensive Cancer Center Vienna, Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe, Hanusch Hospital, Universitätsklinik für Frauenheilkunde und Geburtshilfe, University Medical Center Hamburg-Eppendorf, Wiener Krankenanstaltenverbund, Ordensklinikum Linz Barmherzige Schwestern, Amgen (United Kingdom), Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Klinikum Wels-Grieskirchen, Universitäts Frauenklinik, LKH Hochsteiermark, Otto Wagner Hospital, Siemens Healthineers (Germany), Austrian Breast & Colorectal Cancer Study Group, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Daniel den Hoed Kliniek, Österreichische Krebshilfe Tirol, Medical University of Vienna

OpenAlex ID: A5110178238

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

2011 · Martin Filipits, Margaretha Rudas, et al. · Clinical Cancer Research · 740

PDF

Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma

2001 · Ignace Vergote, Jos De Brabanter, et al. · The Lancet · 622

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

2015 · Michael Gnant, Georg Pfeiler, et al. · The Lancet · 567

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

2022 · C.E. Geyer, J.E. Garber, et al. · Annals of Oncology · 505

PDF

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

2014 · M. Gnant, B. Mlineritsch, et al. · Annals of Oncology · 318

PDF

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

2019 · Michael Gnant, Georg Pfeiler, et al. · The Lancet Oncology · 245

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

2021 · Michael Gnant, Florian Fitzal, et al. · New England Journal of Medicine · 165

PDF

EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.

1997 · J Fischer-Colbrie, A Witt, et al. · PubMed · 155

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

2017 · Marco Colleoni, Weixiu Luo, et al. · The Lancet Oncology · 121

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival

1996 · R.D. Gelber, B.F. Cole, et al. · The Lancet · 115

Young Age as an Independent Adverse Prognostic Factor in Premenopausal Patients with Breast Cancer

2002 · Peter C. Dubsky, Michael F.X. Gnant, et al. · Clinical Breast Cancer · 112

Prognostic factors for survival in Stage I epithelial ovarian carcinoma

1990 · Paul Sevelda, Norbert Vavra, et al. · Cancer · 110

Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study

1992 · Ondansetron Study Group, C Seynaeve, et al. · British Journal of Cancer · 101

PDF

Prognostic value of the rupture of the capsule in stage I epithelial ovarian carcinoma

1989 · Paul Sevelda, Christian Dittrich, et al. · Gynecologic Oncology · 100

Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group

2012 · Peter C. Dubsky, Raimund Jakesz, et al. · Journal of Clinical Oncology · 99

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

2019 · Ignace Vergote, Giovanni Scambia, et al. · The Lancet Oncology · 91

PDF

Microvessel density and vessel invasion in lymph‐node‐negative breast cancer: Effect on recurrence‐free survival

1995 · Andreas Obermair, Christine Kurz, et al. · International Journal of Cancer · 89

The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients

1998 · Andreas Obermair, Alessandra Handisurya, et al. · Cancer · 70

Color-coded and spectral Doppler flow in breast carcinomas – Relationship with the tumor microvasculature

1998 · Christian Peters-Engl, Michael Medl, et al. · Breast Cancer Research and Treatment · 64

Three-dimensional video-endoscopy: clinical use in gynaecological laparoscopy

1994 · R. Wenzl, R. Lehner, et al. · The Lancet · 62

CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer

1989 · Paul Sevelda, Michael Schemper, et al. · American Journal of Obstetrics and Gynecology · 62

First report of lymphatic mapping with isosulfan blue dye and sentinel node biopsy in cervical cancer.

2000 · M Medl, C Peters-Engl, et al. · PubMed · 61

Laparoscopic Surgery in Cases of Ovarian Malignancies: An Austria-wide Survey

1996 · René Wenzl, Rainer Lehner, et al. · Gynecologic Oncology · 60

1995 · Martina Schoderbeck, Brunhilde Auer, et al. · Journal of Perinatal Medicine · 59

Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer

2022 · Michael Gnant, Sophie Frantal, et al. · NEJM Evidence · 56

Works count: 331

Citation count: 6,467

H-index: 35

I10-index: 81